- •The German Asthma Net Severe Asthma Registry is collecting long-term data from over 2000 patients.
- •This manuscript reports baseline characteristics of the recruited cohort.
- •Asthma control was suboptimal: more than 30% required emergency asthma treatment.
- •Long-term follow-up will assess whether (and how) asthma control can be optimised.
The German Asthma Net Severe Asthma Registry is collecting long-term data from a large cohort of patients aged ≥6 years with severe asthma. This manuscript presents their baseline characteristics, and identifies relationships with exacerbations and/or poor asthma control.
The registry is collecting routine clinical parameters including: demographics and medical history; disease characteristics (Asthma Control Questionnaire [ACQ]-5, forced expiratory volume in 1 s [FEV1]); exacerbations; and biomarkers (eosinophils, immunoglobulin E [IgE], fractional exhaled nitric oxide [FeNO]).
These analyses include data from 2011 patients at 72 sites (91.9% adult). Children (6–17 years) were more likely to be male, whereas more adults were female (males: children/adults 62%/41%). Most were receiving inhaled corticosteroid/long-acting β2-agonist combinations (78%/81%); 38.0% of adults were receiving systemic steroids. Asthma control was suboptimal in both groups: 21.5%/13.3% were controlled; 10.4%/49.1% were symptomatic; 33.1%/37.2% received emergency asthma treatment in the previous year. Median blood eosinophil (400/238 cells/μL) and IgE levels (494/186 IU/mL) were higher in children; FeNO was lower (19/35 ppb). Patients with ≥2 exacerbations in the previous year had lower FEV1 (absolute and % predicted) and IgE, and higher ACQ-5, FeNO and blood eosinophil levels (all p < 0.05). There was a weak, negative correlation between ACQ-5 and FEV1% predicted in adults (p < 0.001).
These analyses characterise the typical German patient with severe asthma, and provide information on their overall care. Their planned long-term follow-up will assess whether asthma control can be optimised, how best to do so, and most importantly how such optimisation can benefit patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Respiratory Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.Eur. Respir. J. 2014; 43: 343-373https://doi.org/10.1183/09031936.00202013
- Utilization and costs of severe uncontrolled asthma in a managed-care setting.J. Allergy Clin. Immunol. Pract. 2016; 4 (e3): 120-129https://doi.org/10.1016/j.jaip.2015.08.003
- Drivers of health care costs for adults with persistent asthma.J. Allergy Clin. Immunol. Pract. 2018; 6 (e4): 265-268https://doi.org/10.1016/j.jaip.2017.05.026
- Asthma costs and social impact.Asthma Res. Pract. 2017; 3: 1https://doi.org/10.1186/s40733-016-0029-3
- Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.J. Allergy Clin. Immunol. 2012; 129: 1229-1235https://doi.org/10.1016/j.jaci.2012.01.039
- Severe asthma. Lessons learned from the national heart, lung, and blood institute severe asthma research program.Am. J. Respir. Crit. Care Med. 2012; 185: 356-362https://doi.org/10.1164/rccm.201107-1317PP
- On behalf of the British Thoracic Society Difficult Asthma Network, Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry.Thorax. 2010; 65: 787-794https://doi.org/10.1136/thx.2010.137414
- Cross-sectional analysis of the Belgian severe asthma registry (BSAR).Eur. Respir. J. 2014; 44: 2936
- On behalf of the AGAVE Group, RItA: the Italian severe/uncontrolled asthma registry.Allergy. 2018; 73: 683-695https://doi.org/10.1111/all.13342
- The Danish severe asthma register: an electronic platform for severe asthma management and research.Eur. Clin. Respir. J. 2021; 8: 1842117https://doi.org/10.1080/20018525.2020.1842117
- Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.J. Asthma. 2013; 50: 296-301https://doi.org/10.3109/02770903.2012.757780
- The severe heterogeneous asthma research collaboration, patient-centred (SHARP) ERS clinical research collaboration: a new dawn in asthma research.Eur. Respir. J. 2018; 52: 1801671https://doi.org/10.1183/13993003.01671-2018
- International severe asthma registry (ISAR): protocol for a global registry.BMC Med. Res. Methodol. 2020; 20: 212https://doi.org/10.1186/S12874-020-01065-0
- International severe asthma registry: mission statement.Chest. 2020; 157: 805-814https://doi.org/10.1016/J.CHEST.2019.10.051
- Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort.Respir. Med. 2020; 162: 105858https://doi.org/10.1016/j.rmed.2019.105858
- Correlation coefficients: appropriate use and interpretation.Anesth. Analg. 2018; 126: 1763-1768https://doi.org/10.1213/ANE.0000000000002864
- Global Strategy for Asthma Management and Prevention.2021https://ginasthma.org/reports/(accessed)Date accessed: December 21, 2021
- Cluster analysis and clinical asthma phenotypes.Am. J. Respir. Crit. Care Med. 2008; 178: 218-224https://doi.org/10.1164/rccm.200711-1754OC
- The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.BMC Pulm. Med. 2017; 17: 74https://doi.org/10.1186/s12890-017-0409-3
- Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects.J. Allergy Clin. Immunol. 2013; 132: 821-827https://doi.org/10.1016/j.jaci.2013.06.007
- Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study.J. Allergy Clin. Immunol. Pract. 2017; 5 (e8): 144-153https://doi.org/10.1016/j.jaip.2016.07.015
- Severe eosinophilic asthma: a roadmap to consensus.Eur. Respir. J. 2017; 49: 1700634https://doi.org/10.1183/13993003.00634-2017
Published online: February 26, 2022
Accepted: February 23, 2022
Received in revised form: February 22, 2022
Received: November 3, 2021
© 2022 Elsevier Ltd. All rights reserved.